1	Treatment preferences among people at risk of developing tuberculosis: a discrete choice
2	experiment
3	
4	Wala Kamchedzera <sup>1</sup> , Matthew Quaife <sup>2</sup> , Wezi Msukwa-Panje <sup>1</sup> , Rachael M Burke <sup>3</sup> , Liana
5	Macpherson <sup>4</sup> , Moses Kumwenda <sup>1</sup> , Hussein H Twabi <sup>1,5</sup> , Matteo Quartagno <sup>4</sup> , Peter MacPherson <sup>1,3,6</sup> ,
6	Hanif Esmail <sup>4,7*</sup>
7	
8	1. Public Health Research Group, Malawi-Liverpool Wellcome Clinical Research Programme,
9	Blantyre, Malawi
10	
11	2. Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population
12	Health, London School of Hygiene and Tropical Medicine, London, England
13	
14	3. Clinical Research Department, Faculty of Infectious and Tropical Disease, London School of
15	Hygiene and Tropical Medicine, London, England
16 17	4. MRC Clinical Trials Unit at University College London, London, England
18 19	5. Helse-Nord Tuberculosis Initiative, Kamuzu University of Health Sciences, Blantyre, Malawi
20	
21	6. School of Health and Wellbeing, University of Glasgow, Glasgow, Scotland
22 23	7. WHO Collaborating Centre on Tuberculosis Research and Innovation, Institute for Global
24	Health, University College London
25	*Corresponding author
26	E-mail: h.esmail@ucl.ac.uk (HE)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 27 Abstract

Diagnosing and treating tuberculosis (TB) early, prior to bacteriological conformation (e.g. bacteriologically-negative but radiologically-apparent TB) may contribute to more effective TB care and reduce transmission. However, optimal treatment approaches for this group are unknown. It is important to understand peoples' preferences of treatment options for effective programmatic implementation of people-centred treatment approaches.

We designed and implemented a discrete choice experiment (DCE) to solicit treatment preferences
among adults (≥18 years) with TB symptoms attending a primary health clinic in Blantyre, Malawi.
Quantitative choice modelling with multinomial logit models estimated through frequentist and
Bayesian approaches investigated preferences for the management of bacteriologically-negative, but
radiographically-apparent TB.

38 128 participants were recruited (57% male, 43.8% HIV-positive, 8.6% previously treated for TB). Participants preferred any treatment option compared to no treatment (odds ratio [OR]: 0.17; 95% 39 40 confidence interval [CI]: 0.07, 0.42). Treatments that reduced the relative risk of developing TB disease by 80% were preferred (OR: 2.97; 95% CI: 2.09, 4.21) compared to treatments that lead to a lower 41 reduction in risk of 50%. However, there was no evidence for treatments that are 95% effective being 42 preferred over those that are 80% effective. Participants strongly favoured the treatments that could 43 completely stop transmission (OR: 7.87, 95% CI: 5.71, 10.84), and prioritised avoiding side effects 44 45 (OR: 0.19, 95% CI: 0.12, 0.29). There was no evidence of an interaction between perceived TB disease risk and treatment preferences. 46

In summary, participants were primarily concerned with the effectiveness of TB treatments and strongly preferred treatments that removed the risk of onward transmission. Person-centred approaches of preferences for treatment should be considered when designing new treatment strategies. Understanding treatment preferences will ensure that any recommended treatment for probable early TB disease is well accepted and utilized by the public.

## 53 Introduction

Globally, at least 10 million people fall ill with tuberculosis (TB) every year, and an estimated 1.6 million died of TB in 2022 (1). Although some progress has been made in reducing TB incidence and death, particularly in countries that have experienced HIV-driven epidemics in Africa, this has fallen well short of global targets, and has further been worsened by the disruptions to diagnosis and treatment caused by the COVID-19 pandemic (2,3). Additionally, the TB epidemic has become increasingly concentrated in marginalised groups as the overall TB prevalence has reduced (4,5). Therefore, new, person-centred, and effective approaches must be considered to diagnose and treat individuals early.

61 Accelerated approaches are needed to achieve the rapid declines in TB transmission required to eliminate TB. The standard approach to diagnosing disease is through bacteriological confirmation of 62 Mycobacterium tuberculosis (Mtb) in a biological specimen. It is increasingly being recognised that 63 64 there are potential opportunities to diagnose and intervene earlier in the disease process prior to 65 bacteriological conformation which may then contribute to more effective TB prevention and care and 66 interruption in TB transmission (6,7). There are several tests that have been proposed that could identify 67 people during this earlier stage of disease some of which are established, with others currently in 68 development. People with chest X-ray (CXR) signs suggestive of TB, but with negative sputum 69 bacteriology, have an annualised risk of progression to bacteriologically-positive TB of 10%, with an 70 estimated 26% progressing to sputum positivity over 3 years (8). Blood transcriptional signatures are 71 predictive of disease progression over 0-12 months with a positive predictive value of (PPV) of 8.3-10.3% (9). 72

The development of diagnostics that can predict disease progression has been identified as a research priority by WHO (10). However, in recent years, there has been little attention given to the appropriate treatments for people with earlier stages of TB. Firstly, they may have more limited disease requiring less intense or shorter treatment duration than is used for bacteriologically positive disease (11). Second, a positive test predictive of disease progression does not guarantee disease progression. Analyses of historic trials providing treatment to people with CXR changes suggestive of active TB with negative

bacteriology showed number needed to treat to prevent a case of bacteriologically positive TB was 2.5, which is considerably lower than that for preventive treatment of latent TB infection in a general population(12). Modern clinical trials to determine the optimal approach to treatment for probable early TB are needed. However, whilst these are being undertaken (13), it is important to better understand the treatment preferences of people in these earlier stages of TB disease to inform the design of these trials and facilitate more effective programmatic implementation of new treatment approaches.

We therefore conducted the Radio+ TB Study in Malawi to investigate the role of digital chest 85 radiography with computer-aided detection of TB (DCXR-CAD) and a novel transcriptional marker for 86 87 TB diagnosis and prognosis. Embedded in this study, we conducted a discrete choice experiment (DCE). DCEs are a widely-used tool to measure patients' preferences for service characteristics (14-88 16). They have been shown to accurately predict individuals' preferences and choices regarding 89 healthcare services (17). In DCEs, study participants make several choices between interventions 90 91 (alternatives) that have different levels of the same characteristics (attributes). It is assumed that individuals derive utility from these individual attributes, and thus their preferences can be analysed 92 93 through studying their choices in DCEs(18).

Using a DCE, we aimed to investigate people's preferences for the management of the scenario of
having bacteriologically-negative sputum but with a moderate to high risk of future progression to
bacteriologically positive TB.

## 97 Materials and methods

We used a cross-sectional DCE study design to elicit people's preferences for the management of earlyTB disease.

## 100 Study setting & population

The study took place at a busy urban primary healthcare centre in Blantyre, Malawi (Bangwe Health
Centre). The annualised TB case notification rate in Blantyre was 152 per 100,000 in 2020 (19). In
Blantyre 15% of adults aged 18 years or older are living with HIV (20). TB diagnostic services available

at Bangwe Health Centre follow standard Malawi Ministry of Health guidelines (21). Sputum Xpert MTB/Rif testing, TB treatment provision, and HIV testing and treatment were available onsite, with all clinical care provided by nurses and clinical officers, with no physicians available. At the time of the study, there were no treatment guidelines for early TB disease at the clinic. People with signs and symptoms of TB but bacteriologically-negative sputum typically do not start TB treatment, although on occasion might be referred to a tertiary hospital for further investigations or have empiric TB treatment started at the primary healthcare clinic (at the discretion of the treating nurse or clinical officer).

The present study recruited participants enrolled in the Radio+ TB diagnostic study, which included 111 112 adults of at least 18 years of age, irrespective of HIV status, presenting to the study clinic with TB symptoms (cough of any duration) and residing in Blantyre. For this cross-sectional DCE survey, 128 113 Radio+ TB study participants were consecutively recruited after clinical assessment, which included 114 CXR analysed with CAD4TBv6, sputum investigations, and blood testing with a TB Host Response 115 116 blood test developed by Cepheid (Sunnvvale, Ca, USA), but before any results or treatment were provided. Therefore, whether or not the participant actually had bacteriologically-negative sputum and 117 abnormal CXR was not part of the inclusion criteria. 118

### 119 Design and development of the DCE tool

#### 120 Identification of attributes

To design the DCE tool, attributes of TB management were systematically identified. An initial list of attributes was obtained from reviewing literature for the management of TB disease and treatment preference studies. We kept our search broad and did not limit the list to the management of people with a high risk of TB disease, as the literature in this area is limited and treatment guidelines for this group have not been clearly defined. The list was further informed by policy documents such as Malawi National TB and Leprosy Elimination Programme manuals and TB management guidelines.

To further inform the list of attributes and levels, we conducted qualitative interviews to ensure options were appropriate for the context in which the study would take place. The aim of these qualitative interviews was to identify important factors of the management of early TB disease. In-depth interviews

130 were conducted with participants enrolled into the wider diagnostics study. Participants were

131 purposively sampled to achieve a 1:1 ratio of men to women. Saturation of information was reached at

- 132 20 participants. Data were iteratively coded using Nvivo 12, and thematic analysis was employed. Study
- 133 procedures and results are reported elsewhere. Table 1 illustrates the final list of attributes and levels.
- **Table 1:** Final list of attributes and levels

Attribute	Explanation presented to the participant	Attribute Levels
Duration of treatment	The length of time you would have to take treatment if you were at risk of developing TB disease.	<ul> <li>2 months</li> <li>3 months</li> <li>4 months</li> <li>5 months</li> <li>6 months</li> </ul>
Number of tablets that should be taken per dose	How many tablets you would have to take per dose	<ul> <li>2 tablets per dose.</li> <li>4 tablets per dose.</li> <li>6 tablets per dose.</li> </ul>
The reduction in the risk of being unwell with TB disease, after completing treatment	Your risk of TB disease after completing treatment will reduce from 30% to 15% (if attribute level is a 50% reduction).	- 50% - 65% - 80% - 95%
Likelihood of infecting others	Whether you can still infect others after completing treatment.	<ul> <li>Does not stop you from passing TB on to others.</li> <li>Reduces the chances of passing TB on to others by half.</li> <li>Will completely stop you from passing TB on to others.</li> </ul>
Adverse effects from the treatment	Possible harmful side effects from the treatment.	<ul> <li>No side effects.</li> <li>Minimal side effects -generally not noticeable such as brief feeling of sickness.</li> <li>Mild side effects present each day – may make you feel like not enjoying socializing but able to work.</li> <li>Moderate side effects – Bad enough to stop work and see nurse/doctor for help.</li> </ul>
Frequency of follow up irrespective of treatment.	How often you would have to be checked on by health workers.	<ul> <li>None</li> <li>Once a month</li> <li>3 times a month</li> </ul>
Annual travel cost to access care (USD\$)*	How much you would spend travelling from your home to a healthcare facility to access care in a year.	- \$0 - \$2.95 - \$7.38

\*Costs in the DCE tool were expressed in Malawi Kwacha (MKW).USD\$1.00 = MWK812.51 as of

136 14/09/21 (22)

#### 137 Experimental design and construction of DCE choice sets

In constructing the choice sets for the DCE, using a full factorial design would be the most balanced and orthogonal as it contains all possible combinations of attributes and levels (23). However, with a total of 7 attributes and 25 levels this would result in 1024 (4<sup>3</sup> X 2<sup>4</sup> X 1<sup>5</sup>) choice sets, which was impractically large and would result in respondent fatigue (23). Therefore, to make the task manageable, we used a fractional factorial design (23,24), whereby participants were exposed to a random selection of 10 choice sets from the full factorial design.

144 Using the initial choice set we conducted two iterations of cognitive interviews among five participants.
145 We aimed to investigate whether the formulated DCE was comprehensive for the target population.
146 This involved discussions around the presentation and format of the DCE, including the visual aids and
147 wording used. The results of this were then used to iterate and improve upon the DCE tool.

148 Thereafter, we conducted a pilot study among a further five participants to ensure that the most meaningful and efficient design was used for the final study. To ensure the most efficient DCE design 149 was formed, we used NGENE software to formulate different designs that minimised D-error(23). The 150 D-efficiency score refers to the precision with which effects of attributes are estimated in the model 151 152 (24). Formulation of D-efficient choice sets depends on the planned model specification and the assumed parameter values (23). We therefore used the parameters estimated with the pilot data to act 153 as the assumed parameter values to inform the formulation and selection of the most D-efficient design. 154 We also used the piloting process to identify any areas of the DCE's format and the respective visual 155 156 aids that needed further improvement.

The final DCE included 10 choice tasks. We also included an opt-out option of "neither" to ensure the choices made are realistic in allowing patients not to choose treatment. Each choice task included a scenario, where the participant had negative sputum bacteriology and a CXR result suggestive of TB and underwent a further (unspecified) predictive tests with the result providing a hypothetical risk of disease progression. Participants were therefore asked to make their choices between treatments based on each scenario (e.g.: "if you had a positive test result which means your risk of developing TB disease

163 over the next 12 months is xx%, which treatment would you prefer?"). The risk level of disease progression varied with each choice set (50%, 30%, and 10%). This was done to understand whether 164 the known level of disease risk due to a predictive test could influence treatment preferences. We 165 developed visual aids from the cognitive interviews, which were used to explain the meaning behind 166 167 the "risk of TB disease progression" and the attributes. To check consistency in choices we randomly 168 picked one choice task to be repeated at the end of the 10 tasks. We also asked the participants to give 169 a reason as to why they have picked a particular treatment option. This was done to ensure choices made 170 were not random or due to decision fatigue (25).

#### 171 Data analysis

Data were analysed using STATA v14 (College Station, Texas, US) and R version 4.2.2 (R Foundation
for Statistical Computing, Vienna, Austria). Descriptive statistics were used to summarise the data and
to investigate the distribution of key participant characteristics within the study population.

175 We employed quantitative choice modelling by using a multinomial logit model to analyse the choices made by the participants. In this model the dependant variable was the choice made by participants 176 between treatments, and independent variables were the different attributes and their respective levels. 177 In such models, it is assumed that individuals derive their utility or satisfaction from the choices made 178 179 between treatments (18). Therefore, the model-derived coefficients for the different attribute levels provides the marginal effect of each attribute level on the choice of treatment for individuals at risk of 180 TB disease progression, holding all other attributes constant. Coefficients from the multinomial logit 181 model were converted to odds ratios to show the relative effect of each attribute level on the choice of 182 183 treatment as compared to the attribute's base level.

We further evaluated the interaction between the risk of TB disease progression, taken from the hypothetical scenarios, and the different attribute levels to investigate whether the effect of the attributes on preferences varies by the risk of disease progression. Due to there being an insufficient sample size to observe variations according to disease risk, we employed Bayesian methods to construct a multinomial logit model to estimate possible interaction effects. Priors were weakly regularising. We

189 summarised posterior draws to estimate the percentage point difference and uncertainty in the 190 probability of selecting a treatment option due to an attribute level.

#### 191 Ethical approval

Ethical approval was received from the University of Malawi College of Medicine Research Ethics
Committee (P.02/21/3271) and University College London Research Ethics Committee (ID Number:
19219/001). All participants provided written informed consent. If illiterate, participants were asked to
provide a witnessed thumbprint.

## 196 **Results**

197 Participants were recruited from the 14th of September 2021 to the 21st of February 2022. Table 2 shows the study participants' characteristics. Of the 128 participants, 57% were male. Most participants were 198 aged between 35 and 44 years (30.5%). Additionally, most participants (84.4%) reported primary 199 200 education as their highest level of education. 40.6% of participants were self-employed and 23.4% 201 reported having formal employment. The median duration of cough experienced by participants before presenting to the clinic was 21 days (IQR: 14-30). After cough, chest pain was the most common 202 203 symptom experienced by participants (60.9%). Approximately 8.6% of participants had been previously treated for TB. Just under half of the participants reported being HIV positive (43.8%). During the main 204 205 study, 10.2% of the participants initiated TB treatment over 6-months of follow-up.

206

#### **Table 2:** Participant Characteristics N=128

Characteristic		N (%)
0	Male	73 (57.0)
Sex	Female	55 (43.0)
	18-24	24 (18.8)
Age in years	25-34	34 (26.6)
	35-44	39 (30.5)
	≥45	31 (24.2)
Marital status	Married/cohabiting	86 (67.2)
Marital status	Single/ widowed	42 (32.8)
	None	6 (4.7)
Highest advastion level abtained	Primary	108 (84.4)
Highest education level obtained	Secondary (MSCE)	10 (7.8)
	Higher education	4 (3.1)
T itematic	Can read	116 (90.6)
Literacy	Cannot read	12 (9.4)
	Employed	30 (23.4)
	Self-employed	52 (40.6)
Employment	Student/other	3 (2.3)
	Unemployed	43 (33.6)
Median duration of cough in days (IQR	)	21 (14-30)
	Chest pain	78 (60.9)
	Dyspnoea	57 (44.5)
Experienced other TB symptoms	Feeling weak	51 (39.8)
	Fever	54 (42.2)
	Sweating	52 (40.6)
	Weight loss	74 (57.8)
	Yes	11 (8.6)
Previously treated for TB	No	117 (91.4)
	Positive	56 (43.8)
Self-reported HIV status	Negative	65 (50.8)
-	Missing	7 (5.5)

208 MSCE: Malawi School Certificate of Education

209 IQR: Interquartile range. TB: tuberculosis

Table 3 shows the results of the initial multinomial logit model. The presented odds ratios show the odds of choosing a treatment due to an attribute level compared to the attribute's base level.

There was strong evidence that people valued any treatment option over no treatment (p<0.001). Compared to treatments that did not stop transmission, treatments that reduced the chances of transmission by half had 8.4 (95% confidence interval [CI] 6.12, 11.54) times greater odds of being chosen, and those that completely stopped transmission had 7.87 (95% 5.71, 10.84) times greater odds of being chosen. Participants strongly preferred treatments that reduced their risk of developing TB disease by 80% (odds ratio [OR]: 2.97; 95% CI: 2.09, 4.21) and 95% (OR: 1.95; 95% CI: 1.33, 2.85) compared to treatments that lead to a reduction in risk by 50%.

There was strong evidence for participants being opposed to treatments with moderate (OR: 0.19, 95% CI: 0.12, 0.29), mild (OR: 0.22, 95% CI: 0.16, 0.32) and minimal side effects (OR: 0.35, 95% CI: 0.25, 0.50) compared to treatments with no side effects. There was evidence that participants did not prefer treatments that had 6 tablets per dose as compared to those with 2 tablets per dose (OR: 0.60; 95% CI: 0.40, 0.92). Compared to treatments that did not require any follow-up visits, participants preferred treatments with follow-up visits taking place once a month (OR: 2.57; 95% CI: 1.99, 3.33).

There were some counter-intuitive results. With an increase in the number of months required to complete treatment, the odds of participants preferring the treatment also increased (OR: 1.41; 95% CI 1.28, 1.56). Additionally, participants preferred treatments with a higher annual travel cost as compared to those that incurred no cost (OR: 3.49; 95% CI: 2.15, 5.67).

To check the consistency of participants' choices, task 5 was repeated at the end of all the choice setsin the DCE. Of the 128 participants 80.5% chose the same treatment option.

231

#### **Table 3:** Treatment preferences N=128

Attribute	Level	Odds Ratio (95%CI)	*P-value
	2	1	
Number of tablets per dose	4	0.83 (0.63, 1.08)	0.17
	6	0.60 (0.40, 0.92)	0.02
Duration of treatment (months)		1.41 (1.28, 1.56)	< 0.001
	50%	1	
Reduction in risk of developing	65%	0.91 (0.67, 1.24)	0.57
disease after completing treatment	80%	2.97 (2.09, 4.21)	< 0.001
	95%	1.95 (1.33, 2.85)	0.001
	Does not stop transmission	1	
Likelihood of infecting others with TB disease	reduces the chances of transmission by half	8.4 (6.12, 11.54)	< 0.001
	Completely stops transmission	7.87 (5.71, 10.84)	< 0.001
	None	1	
	Minimal	0.35 (0.25, 0.50)	< 0.001
Adverse effects	Mild	0.22 (0.16, 0.32)	< 0.001
	Moderate	0.19 (0.12, 0.29)	< 0.001
	No follow up	1	
Follow up	Once a month	2.57 (1.99, 3.33)	< 0.001
	3 times a month	1.31 (1.01, 1.72)	0.05
	No cost	1	
Annual travel cost	USD\$2.95	2.02 (1.04, 3.93)	0.037
	USD\$7.38	3.49 (2.15, 5.67)	< 0.001
Opting out of treatment		0.17 (0.07, 0.42)	< 0.001

233 CI: Confidence Interval

234 USD\$1.00 = MWK812.51 as of 14/09/22(22)

To explore whether quantification of the risk of TB affected the importance of different attributes, the interaction effect between the risk of TB disease progression and the different treatment attributes were modelled using a Bayesian multinomial logit model. The results of this are illustrated in Figure 1. Generally, the results showed that, regardless of the level of disease risk, participants were more likely to opt for treatment rather than opt out of treatment. There was, however, no significant evidence for a difference in preferences according to the disease risk level for all treatment attributes.

241

242

Fig 1: Interaction effect between risk of TB disease progression and treatment attributes N=128
USD\$1.00 = MWK812.51 as of 14/09/22(22)

245

## 246 **Discussion**

247 We set out to investigate people's preferences for the treatment in the scenario of not having disease bacteriologically confirmed but being presented with a high risk of future disease progression. Our main 248 findings were that, among those at risk of progression to clinical TB, there is a strong preference to take 249 treatment than to not take treatment. This finding was regardless of the level of perceived TB disease 250 251 risk. Furthermore, strong preferences were shown for treatments that were highly effective, such as 252 treatments preventing transmission and those that would likely reduce the risk of disease progression. 253 The main implications of these findings are that to ensure treatment uptake, new treatment strategies 254 should be highly effective both in treating disease and in reducing the risk of transmission. Additionally, for novel treatments that do provide these benefits, it is important to raise and ensure awareness of these 255 benefits among those seeking healthcare to ensure treatment uptake and adherence. 256

In our study, participants were shown to be primarily concerned with cure. This is demonstrated by the 257 258 preference of being on any treatment option as opposed to none; and there being a strong preference for treatment options that reduced their risk of TB disease by at least 80% as compared to treatments 259 260 offering a 50% reduction. This is further illustrated with there being no interaction effect between the risk of disease progression and attribute levels. This is in line with previous studies on preferences for 261 both preventative therapy and treatment for TB as people have been shown to prioritise being 262 completely cleared from infection or disease, and expressed that their motivation for adhering to 263 treatment is the desire to be healthy (26–28). 264

Preferences were strongly dominated by treatment options that reduced the likelihood of *Mtb* transmission. Previous studies employing qualitative interviews and DCEs have shown that a motivating factor for many individuals to initiate preventative TB treatment was to protect close contacts such as family members, especially children (27). Another study looking at public preferences

for interventions that prevent infectious diseases demonstrated that most participants preferred control
measures such as isolation and quarantine in order to prevent the spread of infection to others (29).
Altogether, this suggests that for our study population, protecting others from infection was a main
priority.

273 Concerning the features of treatment, preference for a treatment increased with an increase in the duration of treatment. This is against our expectations as previous studies have demonstrated that people 274 prefer treatments of shorter durations and the reasons for this is to minimise the risk of side effects to 275 276 ensure treatment adherence (27,30). With our DCE study population, it is possible that participants 277 preferred longer durations as opposed to shorter durations because of a lack of confidence in shorter 278 treatments being effective. This may have been influenced by the current TB treatment regimen in Malawi being six months and the participants' strong preference for treatments that are highly effective 279 280 by reducing their risk of disease progression. Although it is possible that participants were unable to 281 understand the attribute within the DCE or the design of the DCE was not able to effectively measure 282 the participants' preferences, we conducted cognitive interviews before the study to minimise this risk. Further qualitative research is needed to validate and improve our understanding of this result. 283

Our results showed that the experience of taking medication was of high priority. There was preference for treatments with a lower pill burden and no to minimal side effects. A previous study also found that the pill burden of TB treatment had a negative impact on the patient's experience and therefore treatment adherence (28). Similarly, previous studies have shown that people viewed side effects as a barrier to treatment adherence (26,27,30). Side effects arising from TB treatment may hinder an individual's quality of life and ability to take part in income generating activities whilst being on treatment. This is crucial for households in low-income countries such as Malawi.

Participants also preferred to have routine follow-up whilst on treatment. However, the optimal frequency of follow-up was once a month. We can speculate that this finding may reflect the awareness of barriers to accessing healthcare in low-income countries, such as distance and poverty (31–33). And once they are at the health facility, individuals often face long waiting times and high costs (33–35).

Guo *et al* (2011) showed that participants that were employed preferred less frequent clinic visits whilst taking TB preventive therapy (27). This may be especially true with our study population since the majority are either employed or self-employed. Overall, this suggests that, most people desire routine follow-up; however this should not come at the expense of forgoing work related or productive activities.

The odds of picking a treatment increased with cost. This was in contrast to our prior expectations and previous literature (28). It has been shown that high costs act as a barrier to accessing care, and individuals with TB often fall victim to catastrophic expenditure (32,33,36). However, participants preferring to be on any treatment as opposed to no treatment is likely to have driven these results. Opting out of treatment would entail not paying anything as treatment is not being accessed. Therefore, the choice of choosing any treatment option over no treatment would have implied that individuals would rather bear a small cost if it meant being on treatment and getting cured.

307 It is important to note that the participants were presented with all attributes and levels of each treatment 308 option therefore allowing them to weigh the costs and benefits of each treatment. In reality, this is not 309 the case, as not all benefits are made known to individuals in advance of seeking treatment. Therefore, 310 the costs faced can still act as a barrier to seeking care despite the treatment being highly effective.

Our results show that 80.5% of the participants selected the same treatment option during the repeated choice tasks. This shows consistency in choices and is broadly in line with other DCEs in the literature, therefore demonstrating internal validity of the results (37).

#### 314 Study limitations

One limitation of this study is that it was not sufficiently powered to explore heterogeneity in people's preferences for early TB treatment across key demographic characteristics. This type of analysis is important because it acknowledges the fact that the population is not completely homogenous and therefore preferences can be influenced by other factors. Identifying these influencing factors can give

us a greater understanding of why different treatments and interventions are accepted at varying degreesin different populations.

This study only recruited individuals with TB symptoms presenting to the clinic. However, it is becoming apparent that a significant proportion of individuals with early TB disease can be asymptomatic. As these participants are not experiencing any symptoms, they may not anticipate being put on treatment for an extended period. Therefore, their preferences for treatment may be different from those that are symptomatic. Future studies should explore the preferences of this group as insights from such studies can give further information on how patient-centred approaches for early TB management can be designed.

Although we asked the participants why they preferred certain treatment options to ensure choices made were not random or due to fatigue, we did not formally record the decision-making process of our study's participants when choosing between treatment options. This data would have been valuable because it would provide further evidence as to why certain treatment attributes were preferred over others. Therefore, we were only able to speculate as to why certain choices were made when discussing the results of this study. Future DCEs should consider this practice to add depth to the results obtained.

## 334 Conclusions

Our study demonstrates that for the treatment of individuals with a risk of TB disease progression, there 335 is a primary concern with the effectiveness of treatment. Additionally, people will strongly consider 336 337 taking treatment if it means reducing or removing the risk of transmission. Therefore, new treatment 338 strategies should ensure that the treatment is highly effective in treating TB disease. Furthermore, our 339 results also have implications on how public health messages around new treatment strategies should be presented and packaged to the public. For instance, if people are aware of the reduction in the risk 340 of TB transmission whilst being on treatment they are more likely to desire early TB treatment and 341 therefore achieve individual and community benefits. Concerning treatment characteristics, the persons 342 343 experience should be considered when designing new treatment strategies as people preferred no to

- 344 minimal side effects, and fewer tablets per dose. Altogether, this will ensure the treatment is well
- 345 accepted and utilized by the public.

## 346 **References**

- 1. World Health Organization. Global tuberculosis report 2023. Geneva; 2023.
- 348 2. World Health Organization. Global Tuberculosis Report 2022. Geneva; 2022.
- World Health Organisation. The end TB strategy: Global strategy and targets for tuberculosis
   prevention, care and control after 2015. Geneva; 2014.
- Feasey HRA, Khundi M, Soko RN, Nightingale E, Burke RM, Henrion MYR, et al. Prevalence of bacteriologically-confirmed pulmonary tuberculosis in urban Blantyre, Malawi 2019–20:
   Substantial decline compared to 2013–14 national survey. PLOS Global Public Health. 2023 Oct 20;3(10):e0001911.
- 5. Khundi M, Carpenter JR, Corbett EL, Feasey HRA, Soko RN, Nliwasa M, et al. Neighbourhood
  prevalence-to-notification ratios for adult bacteriologically-confirmed tuberculosis reveals
  hotspots of underdiagnosis in Blantyre, Malawi. PLOS ONE. 2022 May 23; 17(5):e0268749.
- Esmail H, Cobelens F, Goletti D. Transcriptional biomarkers for predicting development of
   tuberculosis: progress and clinical considerations. Eur Respir J. 2020 Mar 5; 55(3).
- Drain PK, Bajema KL, Dowdy D, Dheda K, Naidoo K, Schumacher SG, et al. Incipient and
   Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection. Clin
   Microbiol Rev. 2018 Jul 18;31(4).
- Sossen B, Richards AS, Heinsohn T, Frascella B, Balzarini F, Oradini-Alacreu A, et al. The natural history of untreated pulmonary tuberculosis in adults: a systematic review and meta-analysis. The Lancet Respiratory Medicine. 2023 Apr 1;11(4):367–79.
- Gupta RK, Turner CT, Venturini C, Esmail H, Rangaka MX, Copas A, et al. Concise whole
   blood transcriptional signatures for incipient tuberculosis: a systematic review and patient-level
   pooled meta-analysis. The Lancet Respiratory Medicine. 2020 Apr 1; 8(4):395–406.
- World Health Organization. Consensus meeting report: development of a Target Product Profile
   (TPP) and a framework for evaluation for a test for predicting progression from tuberculosis
   infection to active disease. 2017.
- 11. Paton NI, Cousins C, Suresh C, Burhan E, Chew KL, Dalay VB, et al. Treatment Strategy for
   Rifampin-Susceptible Tuberculosis. New England Journal of Medicine. 2023 Mar
   9;388(10):873–87.
- 375 12. Gray AT, Macpherson L, Carlin F, Sossen B, Richards AS, Kik SV, et al. Treatment for
  376 radiographically active, sputum culture-negative pulmonary tuberculosis: A systematic review
  377 and meta-analysis. PLOS ONE. 2023 Nov 16; 18(11):e0293535.
- Scriba TJ, Fiore-Gartland A, Penn-Nicholson A, Mulenga H, Mbandi SK, Borate B, et al.
  Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial. The
  Lancet Infectious Diseases. 2021 Mar 1; 21(3):354–65.

medRxiv preprint doi: https://doi.org/10.1101/2023.12.20.23300332; this version posted December 24, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .


- 381 14. Mangham LJ, Hanson K, McPake B. How to do (or not to do) ... Designing a discrete choice experiment for application in a low-income country. Health Policy and Planning. 2009 Mar 1 382 383 ;24(2):151-8.
- 384 15. Weber S. A Step-by-Step Procedure to Implement Discrete Choice Experiments in Qualtrics. Social Science Computer Review. 2019 Nov 3; 0894439319885317. 385
- 386 16. Soekhai V, de Bekker-Grob EW, Ellis AR, Vass CM. Discrete Choice Experiments in Health 387 Economics: Past, Present and Future. PharmacoEconomics. 2019 Feb 1 ;37(2):201–26.
- 388 17. Quaife M, Terris-Prestholt F, Di Tanna GL, Vickerman P. How well do discrete choice experiments predict health choices? A systematic review and meta-analysis of external validity. 389 390 Eur J Health Econ. 2018 Nov;19(8):1053-66.
- 18. Amaya-amaya M, Gerald K, Ryan M. Discrete choice experiments in a nutshell. In: Using 391 392 discrete choice experiments to value health care. Springer; 2008. p. 13-4.
- 393 19. Soko RN, Burke RM, Feasey HRA, Sibande W, Nliwasa M, Henrion MYR, et al. Effects of Coronavirus Disease Pandemic on Tuberculosis Notifications, Malawi. Emerg Infect Dis. 2021 394 Jul;27(7):1831–9. 395
- 396 20. Malawi Ministry of Health. Malawi Population-based HIV Impact Assessment 2020-2021 397 (MPHIA 2020-2021): Final Report. Lilongwe: MOH, Malawi; 2022 Nov.
- 21. Ministry of Health. Malawi National Tuberculosis Control Programme Manual 8th edition. 398 399 Government of Malawi; 2017.
- 22. Foreign Exchange Rates Reserve Bank of Malawi [Internet]. [cited 2020 Oct 21]. Available 400 401 from: https://rbm.mw/Statistics/MajorRates
- 402 23. Reed Johnson F, Lancsar E, Marshall D, Kilambi V, Mühlbacher A, Regier DA, et al. 403 Constructing Experimental Designs for Discrete-Choice Experiments: Report of the ISPOR 404 Conjoint Analysis Experimental Design Good Research Practices Task Force. Value in Health. 405 2013 Jan 1 ;16(1):3–13.
- 406 24. Lancsar E, Louviere J. Conducting Discrete Choice Experiments to Inform Healthcare Decision Making. Pharmacoeconomics. 2008 Aug 1 ;26(8):661-77. 407
- 408 25. Campbell D, Boeri M, Doherty E, George Hutchinson W. Learning, fatigue and preference 409 formation in discrete choice experiments. Journal of Economic Behavior & Organization. 2015 410 Nov 1;119:345-63.
- 411 26. Lim RK, Semitala FC, Atuhumuza E, Sabiti L, Namakula-Katende J, Muyindike WR, et al. 412 Patient choice improves self-efficacy and intention to complete tuberculosis preventive therapy in a routine HIV program setting in Uganda. PLoS One. 2021;16(2):e0246113. 413
- 414 27. Guo N, Marra CA, FitzGerald JM, Elwood RK, Anis AH, Marra F. Patient Preference for Latent Tuberculosis Infection Preventive Treatment: A Discrete Choice Experiment. Value in Health. 415 416 2011 Sep 1 ;14(6):937–43.
- 417 28. Aibana O, Dauria E, Kiriazova T, Makarenko O, Bachmaha M, Rybak N, et al. Patients' 418 perspectives of tuberculosis treatment challenges and barriers to treatment adherence in Ukraine: 419 a qualitative study. BMJ Open . 2020 Jan 1 ;10(1):e032027.

- 420 29. Cook AR, Zhao X, Chen MIC, Finkelstein EA. Public preferences for interventions to prevent emerging infectious disease threats: a discrete choice experiment. BMJ Open. 2018 Feb 1 421 422 ;8(2):e017355.
- 30. Yuen CM, Millones AK, Galea JT, Puma D, Jimenez J, Lecca L, et al. Toward patient-centered 423 tuberculosis preventive treatment: preferences for regimens and formulations in Lima, Peru. 424 BMC Public Health. 2021 Jan 11;21(1):121. 425
- 426 31. Marahatta SB, Yadav RK, Giri D, Lama S, Rijal KR, Mishra SR, et al. Barriers in the access, 427 diagnosis and treatment completion for tuberculosis patients in central and western Nepal: A 428 qualitative study among patients, community members and health care workers. PLOS ONE. 429 2020 Jan 15 ;15(1):e0227293.
- 32. Muttamba W, Tumwebaze R, Mugenyi L, Batte C, Sekibira R, Nkolo A, et al. Households 430 experiencing catastrophic costs due to tuberculosis in Uganda: magnitude and cost drivers. BMC 431 Public Health. 2020 Sep 16;20(1):1409. 432
- 433 33. Kamchedzera W, Maheswaran H, Squire SB. Economic costs of accessing tuberculosis (TB) 434 diagnostic services in Malawi: an analysis of patient costs from a randomised controlled trial of 435 computer-aided chest x-ray interpretation [version 1; peer review: 2 approved with reservations]. Wellcome Open Research. 2021 ;153(6). 436
- 34. Sichali JM, Khan JAK, Gama EM, Banda HT, Namakhoma I, Bongololo G, et al. Direct costs of 437 illness of patients with chronic cough in rural Malawi-Experiences from Dowa and Ntchisi 438 439 districts. PloS One. 2019;14(12):e0225712.
- 35. Ukwaja KN, Alobu I, Lgwenyi C, Hopewell PC. The High Cost of Free Tuberculosis Services: 440 441 Patient and Household Costs Associated with Tuberculosis Care in Ebonyi State, Nigeria. PLoS ONE. 2013 ;8(8). 442
- 443 36. Fuady A, Houweling TAJ, Mansyur M, Richardus JH. Catastrophic total costs in tuberculosis-444 affected households and their determinants since Indonesia's implementation of universal health 445 coverage. Infectious Diseases of Poverty. 2018 Jan 12;7(1):3.
- 446 37. Johnson FR, Yang JC, Reed SD. The Internal Validity of Discrete Choice Experiment Data: A Testing Tool for Quantitative Assessments. Value in Health. 2019 Feb 1;22(2):157-60. 447

#### Supporting information 448

- 449 S1 Appendix. Discrete choice experiment questionnaire (English)
- 450 S2 Appendix. Discrete choice experiment guestionnaire (Chichewa)
- 451 S3 Appendix. Discrete choice experiment visual aid.





# Figure 1